Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
Eli Lilly and Company
Thomas Jefferson University
Thomas Jefferson University
National Cancer Institute (NCI)
Mayo Clinic
University of Illinois at Chicago
Memorial Sloan Kettering Cancer Center
Yale University